论文部分内容阅读
目的评价TCT联合HPV在子宫颈病变的诊断价值。方法对发现宫颈异常的患者同时TCT(ThinPrep Cytology Test)及高危HPV检测,对一项或两项异常者行病理组织学检查,并以病理结果为金标准。对380例病理结果阳性(CINⅠ、CINⅡ、CINⅢ、宫颈浸润癌)的患者,比较两种方法的检出敏感度。结果TCT检测阳性者301例,敏感度为79.2%,HPV DNA检测阳性329例,敏感度86.6%,与TCT检测的敏感度相比差异有统计学意义(P<0.05))。结论对于宫颈癌及其癌前病变的筛查及早期诊断,应以宫颈细胞学检查和高危HPV检测相互结合以提高检出率,降低假阴性。
Objective To evaluate the diagnostic value of TCT combined with HPV in cervical lesions. Methods Both ThinPrep Cytology Test (TCT) and high-risk HPV test were performed in patients with cervical abnormalities. Pathological examination was performed on one or two abnormal patients, and pathological results were taken as gold standard. In 380 patients with pathologically positive results (CIN I, CIN II, CIN III, invasive cervical cancer), the detection sensitivity of the two methods were compared. Results There were 301 cases with positive TCT test, the sensitivity was 79.2%, HPV DNA test was positive in 329 cases, the sensitivity was 86.6%, which was significantly different from the sensitivity of TCT test (P <0.05). Conclusion For the screening and early diagnosis of cervical cancer and precancerous lesions, cervical cytology and high-risk HPV testing should be combined to improve the detection rate and reduce false negatives.